Cx501 is used to treat epidermolysis bullosa (EB), a rare genetic condition which can lead to contraction of the joints, fusion of fingers and toes, contraction of the mouth membranes... It is developed by Cellerix and is in phase I of clinical trials.
- Mechanism
- Curator reviewed
Cx501 is an artificial skin graft obtained from bringing together keratinocytes from the patient and skin fibroblasts from a healthy donor. Both components are embedded in a plasma matrix which provides the adequate environment for natural healing to occur. These healthy fibroblasts provide the patient with the structural protein that is lacking in the skin of Epidermolysis bullosa (EB)patients.
- Primary indication
- Investigated for use/treatment in skin infections/disorders.Curator reviewed
- Code names
- CX501
What you can answer from here — as of April 02, 2025
Which companies are running trials of CX501, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account